Compare Heron Therapeutics Inc (HRTX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while iShares 20 Plus Year Treasury Bond ETF trades at $77.96 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 700× Heron Therapeutics Inc's market cap, and iShares 20 Plus Year Treasury Bond ETF is more actively traded (49,263,490 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| HRTX | TLT | |
|---|---|---|
Market Cap | $68.01M | $47.61B |
Volume | 1,891,941 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $92.06 |
52-Week Low | $0.27 | $77.11 |
Typical Hold Time | 35 Days | 83 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
TLT, the iShares 20+ Year Treasury Bond ETF, is trading at $77.83 with a 0.89% daily gain amid a challenging bond market environment. The ETF has declined 11% year-to-date and 46% over five years as Treasury yields reach multi-decade highs. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights significant bond market volatility with Treasury yields hitting levels not seen since 2007.
The outlook for TLT remains heavily dependent on interest rate direction, with current high yields presenting both income opportunity and continued price risk. Key risks include persistent inflation pressures and Federal Reserve policy uncertainty. Investors should weigh the attractive yield against potential further bond price declines if rates continue rising.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
